Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

A total of 709 patients were enrolled in CheckMate 274, including 353 patients (of whom 140 patients had PD-L1 ≥ 1%) who were randomly assigned to take nivolumab 240 mg every 2 weeks ...

In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...

Combination treatment with nivolumab and cabozantinib provides long-term benefits over sunitinib in patients with advanced RCC, according to final results from the CheckMate 9ER trial.